To evaluate the role of UCBT in adults, we have analyzed 108 patients with malignancies, reported to the Eurocord and transplanted from 12/1994 to 01/2000. Median age was 26 y (15-53), median weight was 60 kg (35-110) and median follow-up time was 20 months (06-60). Fifty-five patients had Acute Leukemia (AL), 37 CML, 4 NHL and 12 MDS. Forty-seven patients were transplanted with good-risk status (AL in CR1/2 and CML in CPh). Twenty patients (19%) were previously given an autoBMT. GVHD prophylaxis consisted mainly in CsA+ prednisone (n=77). Conditioning regimen varied according to diseases and centers. Six patients received an HLA identical (HLA-A, -B serology and -DRB1 allelic typing) unit and 102 an HLA mismatched (1 HLA difference in 38, 2 HLA diff in 51 cases, 3 HLA diff in 13). The median number of nucleated cells infused (NCI) was 1.7x107/kg (0.2-6). Results: Neutrophil recovery at day 60 was 81% and platelet recovery at day 180 was 65%. 24 patients died early between day 4 and 57 and 15 did not engraft. Median days for ANC Ͼ 500/mm3 and platelets (Ͼ20.000/mm3) were 32 days (13-57) and 129 days (26-176), respectively. NCI Ͼ1.7x107/kg was an important factor influencing neutrophil and platelet recovery (p=0.01) Acute GVHD (Ͼ grade II) was observed in 44 patients. The occurrence of grade III-IV (n=27) GVHD was not influenced by the number of HLA disparities (p=0.12). Chronic GVHD was observed in 15 of 58 patients at risk. Kaplan-Meier estimate for transplant-related mortality at day 100 (TRM) was 54%.Patients transplanted before 01/98 received CB units containing fewer number of cells (p=0.03) and more HLA diff (p=0.001) compared to those patients transplanted after 01/98. In multivariate analyses the risk of 100 day TRM was influenced by: 1) status of the disease at CBT (RR:1.85; p=0.03), 2) NCI Ͼ1.7x107/kg (RR: 1.2; p=0.04) and 3) transplant performed before 01/98 (RR:1.90; p=0.02). One year-survival was 27% and EFS was 21%. Favorable factors for survival were 1)NCI Ͼ1x107 NC/kg (p=0.014) and 2) good-risk status at transplant (p= 0.007). Ten out of 11 patients receiving Ͻ1x107 NCI/kg died. Probability of survival at 1 yr was 33% for patients receiving more than Ͼ2x107 NCI/kg and 39% for patients in good-risk status at transplant (p=0.007). Seventy-four patients died: 7 (9%) of relapse; 30 (41%) of non engraftment and infections, 17 of toxicity (23%); 13 (18%) of GVHD and 7 of other causes. In conclusion, these results suggest that UCBT is an optional source of stem cells in adults with malignancies lacking a matched unrelated donor. The choice of units containing large number of cells and good disease status at transplant might improve results.
The potential role of UD-CBT in adult patients is uncertain due to both small numbers and great heterogeneity of patients. The aim of this study was to evaluate the preliminary results of UD-CBT in a homogeneously treated series of adults with hematologic malignancies lacking an HLA-identical family or unrelated donor. From May 1997 to July 2000, 16 patients (9F/7M; median age 27 yr, range 18-46 yr) received an UD-CBT. Diagnosis were CML in nine (five in 1st chronic phase, one in 2nd chronic phase, one in accelerated phase and two in blast phase), high-risk ALL in five, secondary AML in one and RAEBT in one. One CB unit was HLA matched (HLA-A, and -B by serology and -DRB1 by high-resolution DNA allelic typing), nine were mismatched at one HLA antigen and six were mismatched at two HLA loci. The median (range) number of infused nucleated cells, CD34+ cells and CFU-GM colonies was 1.7 x 10E7/kg (1.2-4.9), 0.7 x 10E5/kg (0.3-2.6) and 1 x 10E4/kg (0.1-5.6), respectively. Fifteen patients received thiotepa (10 mg/kg), busulfan (12 mg/kg), cyclophosphamide (120 mg/kg) and anti-thymocyte globulin (Lymphoglobuline (R) 60 mg/kg) as conditioning. One, who did not engraft after previous allogeneic peripheral blood stem cell transplantation from an UD, received fludarabine (150 mg/m2), thiotepa (as above) and anti-thymocyte globulin (as above).
Graft-versus-host disease (GVHD) prophylaxis consisted in cyclosporine and prednisone, and CMV prophylaxis in aciclovir followed by ganciclovir. All patients received G-CSF from day +7 until engraftment. All 14 evaluable cases had myeloid engraftment. Median time (range) to Ͼ0.1, Ͼ0.5 and Ͼ1 x 10E9 PMN/L was 14 (12-30), 22 (17-52) and 27 (18-64) days respectively. In eight cases evaluable for platelet engraftment median time (range) to Ͼ20 and Ͼ50 x 10E9 platelets/L was 67 (50-128) and 96 (60-139) days. Complete donor chimerism was demonstrated (PCR-VNTR, PCR-SSP to HLA disparities and/or FISH XY) at a median of 14 days (range 14-36). Five patients developed Ͼgrade II acute GVHD, and all nine patients at risk developed chronic GVHD (extensive in four). Seven patients have died and nine remain alive and disease-free (four CML, three ALL, one secondary AML and one RAEBT) between 3+ and 41+ months after UD-UCBT. These results suggest that UD-CBT may be a reasonable approach in adult patients with hematologic malignancies lacking an appropriate related or unrelated bone marrow donor.
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Influence of preparative regimen and methotrexate for GVHD prophylaxis on engraftment after related cord blood transplant for patients with haemoglobinopathies: an EUROCORD Group analysis F. Locatelli, V. Rocha, M. Ertem, S. Graphacos, F. Bernaudin, X. Li, B. Brichard, A. Nagler, R. Miniero, I. Roberts, I. Yaniv, P. Lutz, A. Will, T. Raja, F. Garnier, E. Gluckman on behalf of EUROCORD Group (Pavia, I; Paris, F; Torino, I) Autologous reconstitution is a major problem after cord blood transplant (CBT) for patients with haemoglobinopathies (Hbpathies). We analysed risk factors for neutrophil engraftment in 31 patients with Hbpathies (Sickle cell disease (SCD) n=6, and Thalassaemia (Thal) n=25) receiving a related CBT in 15 transplant centres. All CB donors were HLA matched, except one (1 HLA-A difference). Median recipient age was 5 years (1-19) and median follow-up was 24 months (2-72). At transplant, 19 and 12 patients belonged to class 1 and class 2 of the Pesaro classification, respectively. One patient with SCD had previously had stroke. As preparative regimen, 17 patients received Cyclophosphamide (CY) associated to Busulfan (BU) and 14 patients were given CY+BU associated to Thiotepa (THIO) (n=9) or Fludarabine (FLU) (n=5). ATG was associated in 12 cases. GVHD prophylaxis consisted of either Cyclosporine A (CsA) alone (n=23) or associated to Methotrexate in 8 cases. Median number of nucleated cells infused was 3.8 x 107/kg (1.2-10). Prophylactic haematopoietic growth factors (Ͻday 8) were administered to 20 patients. Patient-, disease-and transplant-related factors were analysed for neutrophil recovery. Results: Median time for neutrophil (Ͼ500/mm3) and platelet (Ͼ20.000/mm3) recovery was 21 (9-33) and 39 days (13-74), respectively. At day 60, probability of neutrophil recovery was 79%. Seven patients had autologous haematopoietic reconstitution (SCD=1 and Thal=6). Patients receiving CY+BU as preparative regimen had 67% of probability of neutrophil recovery as compared to 93% for those receiving CY+BU associated to THIO or FLU (p=0.002). Another factor influencing speed and probability of neutrophil recovery was the addition of MTX to CsA. Probability of neutrophil recovery was 38% for patients receiving MTX, compared to 91% for those receiving CsA alone (p=0.02). At last follow-up, 20 patients were full chimera, 3 had mixed chimerism and in 1 patient this information is not available. Acute GVHD (grade ϾII) and chronic GVHD were observed in only two patients. All patients are alive and two-year disease free survival (with transfusion independence) is 71%. In conclusion, CY+BU associated to a third drug (THIO or FLU) and absence of MTX for GVHD prophylaxis, increases probability of neutrophil recovery without increasing toxicity and the incidence of GVHD in patients receiving a related CBT for Hbpathies.
P354
Decreased engraftment capacity of ex vivo expanded umbilical cord blood progenitors in nod-scid mice is associated with a reduced adhesion capacity mediated through a4b1 and a5b1 integrins F. Prosper, M. Ramirez, J.C. Segovia, I. Benet, C. Arbona, G. Guenechea, G. Guenechea, C. Blaya, J. Garcia-Conde, J. Bueren (Valencia, Madrid, E) We have analyzed the effect of ex vivo expansion of umbilical cord blood progenitors (UCB) on the expression and function of adhesion molecules involved in homing and engraftment of hematopoietic progenitors using the NOD/SCID mouse model. Expansion of CD34+ UCB cells for 6 days with IL3, IL6 and SCF (EE1) and with IL11, SCF and Flt3 (EE2) increases the expression of a4, a5, b1, aM and b2 integrins in CD34+. However, despite increased expression of integrins, adhesion of CFU-GM to fibronectin (FN) was significantly reduced (22 ± 4% in fresh CFC versus 5 ± 2% and 2 ± 2% in EE1 and EE2 samples). When samples were incubated with the activating b1 integrin antibody TS2/16, the adhesion of EE CFU-GM to FN or to FN fragments harboring a4 and a5 binding domains was markedly increased. When fresh and EE samples, treated or not with TS2/16, were transplanted into NOD/SCID mice, a significant reduction in the short-term engraftment of the animals was associated to EE of UCB, in good consistency with our previous studies. However, the activation of b1 integrins with TS2/16 almost completely abrogated the repopulating ability of the fresh and also the EE samples. The analysis of the seeding efficiency of the ex vivo manipulated samples (% of human cells in the BM, blood and spleen 24 hours after infusion of UCB cells into NOD/SCID mice) showed that no marked effects on the seeding efficiency of CD34+ could be associated with the EE of the sample. However, the activation of b1 integrins with TS2/16 mediated a marked reduction in the seeding efficiency of human CD34+ cells both to the BM and to the spleen of NOD/SCID recipients. Our results show that activation of the b1 integrin could overcome the detrimental effect of ex vivo expansion on the VLA-4 and VLA-5 mediated adhesion of hematopoietic progenitors in vitro. In vivo, however, these effect was associated with an almost complete abrogation of homing and repopulating ability of UCB cells. .045). In 39 patients, immune reconstitution was determined at 1,3,6 and 12 months post-transplant and it was seen that use of PBSC was associated with higher CD4 count (0.17 vs.0.09, p=0.032) and CD25 count (0.073 vs. 0.04, p=0.007) at 1 month, but there were no differences there after. Allo-PBSC had lesser chance of lymphocyte count less than 0.5x109/l at 1 month (33% vs. 74%, p=0.03). Of various pre-transplant factors disease stage independently predicted relapse risk (RR: 3.02, 95%CI:1.6-5.7, p=0.004). Dose of MNC, lymphocytes or lymphocyte subtypes did not influence TRM, relapse or OS. Patients who had CD4+ counts above 0.13x108/l at day +28 had significantly lower TRM (12% vs. 46%, p=0.0132) and better OS (82% vs. 44%, p=0.0233) but the relapse risk was similar (14% vs. 29%, p=0.147) . This single centre analysis shows that use of PBSC is associated with early immune reconstitution and has significantly lower risk of relapse. Whether better OS with rapid CD4 recovery is due to less TRM or reduced risk of relapse needs to be evaluated in larger patient population. . GVHD prophylaxis mostly consisted of CyA+MTX (n=258, 79%) or CyA+PDN (n=66, 20%). Results: Faster neutrophil recovery was observed in patients not receiving MTX (pϽ0.0001) and in those transplanted with a CD34+ cell dose Ͼ5x10e6/kg (p=0.014). Probabilities of grades II-IV and III-IV acute GVHD (aGVHD) were 52% and 29%, respectively. The probability of chronic GVHD (cGVHD) was 70%. In the multivariate analysis, factors influencing cGVHD were: grades II-IV aGVHD (p=0.001), male patients with female donor (p=0.003) and GVHD prophylaxis without MTX (for cGVHD appearing 6 months postransplant) (p=0.03). After a median follow-up of 26 months, 182 (56%) patients remain alive. Overall (OS) and disease-free survival (DFS) probabilities at 30 months were 46% and 43%, respectively. Early and intermediate stage of disease (p=0.0001), conditioning with chemotherapy (p=0.008), GVHD prophylaxis with MTX (p=0.04) and grades 0-1 aGVHD (p=0.003) were independent factors associated with a better DFS in multivariate analysis. The probability of TRM at one year was 26%. In the multivariate analysis factors associated with an increased TRM were: grade II-IV aGVHD (pϽ0.0001), cGVHD (p=0.01) and conditioning with TBI (p=0.01). Of note, OS and DFS for 120 patients with acute leukemia transplanted in Ͻ 2nd CR were 53 % and 48% respectively. Also remarkable was the 76% DFS at 4 years in 43 patients transplanted for CML in first CP. In conclusion, allo-PBT results in high incidence of cGVHD. Early and intermediate stage of disease, conditioning with chemotherapy alone, GVHD prophylaxis with MTX and grades 0-1 aGVHD were associated with better DFS and lower TRM. The good outcome of patients with early or intermediate stage acute leukemia and CML in 1st CP provides background to investigate a possible benefit over marrow transplants in these settings.
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Cytomegalovirus-seropositivity of the patient with or without reactivation is the most important factor for treatment related mortality in stem cell transplantation from unrelated donors using pretransplant anti-thymocyte globulin N. Krö ger, T. Zabelina, W. Krueger, H. Renges, N. Stute, J. Schrum, H. Kabisch, G. Amtsfeld, C. Loeliger, A. Hinke, A.R. Zander (Hamburg, D)
We evaluated the cytomegalovirus (CMV) serostatus as risk factor for survival and treatment related mortality (TRM) in 125 patients allografted from unrelated donor between 1994 and 1999. All patients received pretransplant in vivo T cell depletion using rabbit anti-thymocyte globulin (ATG). Only one patient had primary graft-failure and severe grade III/IV GvHD occured in 14% of the patients. The overall survival (OS) at three years was 70% for CMV negative patients (n=76) and 29% in the seropositive cohort (n=49) (pϽ0.001). In a multivariate analysis CMV seropositivity remained an independent negative prognostic factor for OS (RR:2.1; CI:1.2 to 3.8; p=0.014), besides age Ͼ20 years (RR:2.74; CI:1.2 to 3.8; p=0.004), late leukocyte engraftment (RR:2.4; CI:1.2 to 4.9; p=0.015) and disease-status at transplantation (RR:3.4;CI:1.8 to 6.5; p=0.015). The TRM for all patients was 27%. Despite monitoring for CMV antigenemia and peemptive therapy with ganciclovir in case of reactivation, seropositive patients had a three times higher risk of fatal treatment related complications than seronegative patients. In multivariate analysis CMV-seropositivity remained the strongest independent negative factor for TRM (RR:5.3; CI:1.9 to 14.6; p=0.002), followed by age Ͼ20years (RR:4.8; CI:1.3 to 18.1; p=0.02) and delayed leukocyte engraftment (RR:3.6; CI:1.2 to 11; p=0.02). The TRM was identical in seropositive patients with (n=27) or without (n=22) CMV-reactivation (44% vs 50%). We conclude that CMV seropositivity, despite preemptive ganciclovir therapy and even without reactivation, is a major negative prognostic factor for survival as well as for TRM in unrelated stem cell transplantation using pretransplant in vivo T-cell depletion with ATG. The clinical results between 107 patients receiving a G-CSF mobilised peripheral blood progenitor cell graft (PBPC) graft from an HLA-A, -B and -DR compatible unrelated donor were compared to 107 matched controls receiving an unrelated bone marrow (BM) transplant. Engraftment was achieved in 94% of the patients in both the PBPC and the BM group. The PBPC graft contained significantly more nucleated cells, CD34+, CD3+ and CD56+ cells (pϽ0.001) and resulted in a significantly shorter time to neutrophile (15 vs 19 days) and platelet engraftment (20 vs 27 days) compared to the BM control group (pϽ0.001). Probability of acute GVHD II-IV were 35% and 32% (ns), and probability of chronic GVHD were 61% and 76% (ns), in the PBPC and BM groups, respectively. There was no difference in bacteraemia, CMV reactivation, CMV disease and fungal infection between the two groups. Three years transplant related mortality (TRM) was 42% in the PBPC group and 31% in the BM controls (ns) and survival was 46% and 45%, respectively. Among patients with a malignant disease, probability of relapse was 25% and 31% in the two groups, respectively (ns), resulting in a disease-free survival of 43% in the PBPC group and 46% in the BM controls (ns). In multivariate analysis early disease, acute GVHD 0-I and presence of chronic GVHD were independent factors associated with a better disease-free survival in this study. Conclusion: PBPC from HLA-compatible unrelated donors gives faster engraftment compared to bone marrow, but has otherwise a similar outcome. Objective: Since stroma defects are part of SAA etiology and hematopoietic engraftment is poor in unrelated and mismatched transplant we wanted to find out whether hMSC are in part of donor origin in patients with SAA years after successful BMT. Methods: Human mesenchymal stem cells (hMSC) were grown from patients' bone marrow aspirates after informed consent according to the method of Caplan AI et al. using a carefully selected FCS (Haynesworth SE, 1992) . Primary cultures of adherent hMSC were further analyzed by interphase fluorescence in situ hybridization (FISH) analysis using centromer specific DNA probes for X and Y chromosome (DXZ1 and DYZ3, Vysis, IL, USA). For comparison we also analyzed bone marrow MNC after a Ficoll gradient. As evidenced by morphology, immunocytochemistry (APAAP) and flow-cytometry (SH2, SH3 and SH4) a homogeneous adherent population of hMSC was obtained after 2 weeks with Ͻ 0.1 % hematopoietic cells. Unlike stroma, hMSC obtained by this method showed multipotency in differentiation assays in vitro. Results: Two male SAA patients 24 and 46 years old, 5 and 3 years after BMT (Cy, ATG) with filtered marrow from an HLAidentical female sibling donor were investigated. Bone marrow aspirates were taken and analyzed for donor contribution. The ability of the bone marrow to form hMSC was impaired, since the adherent cell number was significantly lower than in normal controls. FISH analysis did not show any evidence of female donor cells in the adherent hMSC : 0.0% and 0.2% out of 500 analyzed cells were XX type which is well within assay limits. In contrast, Ficoll separated MNC (hematopoietic cells) from the same BM aspirate were 100% and 97.5% of donor origin as expected (FISH) . Also data from a female SAA patient after BMT will be presented whose bone marrow apart from FISH is being analyzed for the Y chromosome of her brother by a sensitive and quantitative TaqMan PCR established in our lab. Conclusion : In SAA, like previously found in patients with lysosomal and peroxisomal storage disease (Koc ON, 1999), bone marrow-derived hMSC remain host-derived despite successful hematopoietic engraftment after allogeneic BMT. Cord Blood (CB) is a reliable source of hematopoietic stem cells (HSC) for allogeneic transplant. However, in this setting the HSC engraftment remains a major problem and several retrospective analysis have shown that the cell dose infused significantly affect both the rate of and the time to engraftment and survival. Therefore, the ex-vivo expansion of HSC from CB might represent a promising approach to improve clinical results. With this purpose we have previously standardized a shortterm amplification culture system of CB CD34+ cells (De Felice, Br J Haematol, 106:133, 1999 ) and then developed a NOD/SCID mice model in order to evaluate both the early engraftment and long-term hematopoietic reconstitution potential of the amplified cells. Sixty-one NOD/SCID mice have been transplanted with CD34+ cells amplified with flt3L/SCF/IL-3 over 7-days cultures (input cell number: 4 -7.5 x 10E4 cryopreserved CD34+ cells). The engraftment capability of ex-vivo generated cells has been evaluated at 7, 14, 21, 28 days and 6-12 weeks after transplant by means of (1) cytofluorimetric detection of CD45+ cells in bone marrow (BM) and spleen samples and (2) PCR amplification of human specific sequence (p17H8) on mice BM colony forming cells. NOD/SCID mice (n=20) receiving unmanipulated CD34+ cells were used as controls. A low rate of early (Table 1 , column 3-5) and late engraftment (Table 1, column 6-8) was detected in mice transplanted with either 4 x 10E4 unmanipulated CD34+ cells or amplified cells generated from the same starting cell dose. In mice transplanted with amplified cells obtained from 7.5 x 10E4 CD34+ cells the percentage of both early and late engraftment raised to 61% (11/18) and 100% (5/5) respectively. These data are the first evidence that short-term amplified CB cells can be detected in BM mice as early as 7 days after transplant with a progressive rise of the percentage of engraftment in later controls. These experimental results may have a significant clinical relevance by improving engraftment in CB transplanted patients. The in vitro hematopoietic and stromal cell growth was evaluated at day +20, +35, +60 and +100 and thereafter every 3-6 months. Despite the significantly different number of cells/progenitors infused, the in vitro hematopoietic reconstitution after transplant was quite similar in the two groups of patients. As shown in the figure, in CB transplanted patients the growth of hematopoietic progenitors (CFU) progressively increased by time. In MUD recipients the kinetic of in vitro reconstitution was characterised by a variable growth pattern with a high number of colonies in the first control followed by a significant decrease of the CFU number at day +35. At 2 years after transplant, the clonogenic potential in both groups remained at the low limit of the normal range. In long term cultures stromal cell reconstitution was detected as a confluent layer in 9/13 patients (6/8 CB and 3/5 MUD) only after six months from transplant. Individual-specific VNTR genetic loci were amplified by PCR to determine the donor/host origin of stromal cells. Preliminary results show that in CB recipients the fibroblasts were of host origin, whereas a condition of mixed chimerism was detected in patients transplanted with MUD cells even after removal of macrophages. From the in vitro culture studies we can conclude that: 1) the hematopoietic reconstitution tends to reach a normal pattern by time and seems to be independent from the cell dose infused; 2) the chimerism of stromal cells is absent in CB and mixed in MUD. In 1993 In -1996 , an international donor search took 7,2 months, while it consumed only 3,6 months in the period between 1997 and 1999. 57,6% (143/248) of the patients could be provided with a matching donor between 1993 and 1996, while 74,4% (201/270) of the patients could be supplied with a donor in the later period between 1997 and 1999. While only 3o,6% (76/248) of the patients were transplanted in 1993 -1996, 52,5% (142/270) Since 1988, 278 transplants from unrelated donors could be performed in Austria: 29% of the donors came from Germany, 22% from England, 15% from the U.S.A., 8% of the donors came from Austria, the remaining 26% of the donors originated from 10 other countries.
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of the patients received an unrelated transplant between 1997 and 1999. First results of the year 2000 show, that this trend is continuing in 2000: 88,1% (59/67) of the patients in need fo an MUD analyzed so far in this year could be provided with a donor. 67,1% (45/67) have already received a stem cell transplant.
P363
Peripheral Blood Stem Cells (PBSC) collections in allogeneic healthy donors: a comparison among Spectra, AS Tec204 and CS3000Plus cell separators C.T. Tassi, V.G. Giudice, P.T. Tazzari, F.R. Ricci, G.B. Bandini, R.C. Conte (Bologna, I)
From January 1998 to October 2000, one hundred and forty PBSC harvests were performed in 87 healthy allogeneic donors. Forty two collections were carried out by CS3000Plus equipment, 55 by Spectra-Cobe and 43 by AS TEC 204 cell separators. Aims of the present study were: 1) To evaluate and compare the CD34+ and CD34+CD90+ cells Collection Efficiency (CE) of procedures performed with three different harvesting systems 2) To investigate whether different hematopoietic recovery time in patients submitted to allogeneic PBSC transplantation could be also related to qualitative features of the harvests reinfused.. CD34+ and CD34+CD90+ CE% were assessed Ͼ50% in harvests performed by Spectra and AS TEC 204, while a significant lower CD34+CD90+ CE% was found in CS3000Plus leukoapheresis. Morphological analysis on harvest samples disclosed mean PMN contamination Ͻ6% in 86% of the samples studied, being most prominent the MNC component. However, highest lymphocyte subsets were scored in CS3000Plus aphereses. PMN recovery time was compared in patients according to the harvesting system employed in their donors. Mean day to Ͼ500 PMN was 14.6 in all patients studied. On the contrary, a significant delayed Plt recovery was observed in patients who received CS3000Plus performed leukoapheresis (25.6 days vs18.6 and 19 days, p= 0.0003).
In conclusion, the Spectra and AS TEC 204 systems disclosed similar CE and qualitative features of the apheretic products. CS3000Plus CD34+CD90+ CE was significantly impaired despite appropriate adjustements of the processing software: we believe that this phenomenon could be due to peculiar biological and morphological characters of more primitive hematopoietic progenitors. From a practical point of view, the lower CE of CS3000Plus cell separator resulted in higher number of leukoapheresis performed per healthy donor. As regards clinical implications in allotransplanted patients, extensive studies are ongoing to confirm or exclude positive correlation between kind of cell separator used and hematopoietic reconstitution in selected allotransplanted patients. The detectionof chimerism, residual molecular and cytogenetic disease of transplantation pf PBSC with a none-myeloablative conditioning (n=9) and the transplantation of highly purified CD34+ stem cells (CD34+-PBSCT) (n=16) were compared to unmanipulated BMT (N=69) and PBSCT (n=50) after a myeloablative conditioning in patients with CML 1stCP (n=137), 2nd CP of CML (n=4), ALL (n=2), and AML (n=1). A molecular relapse (MR)as defined by two consecutive positive PCR assays for the detection of bcr-abl (n=141)and cbfb-myh11 (n=1) in a 4-week interval was found in 10 of 16 patients (63%) after CD34+-PBSCT, and in 27 of 69 patients (39%) after BMT, whereas only 3 of 50 patients (6%) after PBSCT (pϽ0.001) and 1 of 8 patients (13%) after PBSCT with reduced conditioning suffered from a MR. A cytogenetic relapse occurred in 5 of 16 patients (31%) after CD34+-PBSCT and 21 of 69 patients (30%) after BMT compared to 2 of 50 patients (4%) after PBSCT and none of 8 patients after PBSCT with reduced conditioning (pϽ0.05). The lowest treatment related mortality was seen in the 16 patients after CD34+-PBSCT, who are all currrently alive with a follow-up observation period at a median of 16 months, whereas the survival rate for BMT, PBSCT and PBSCT-red.conditioning were 65%,63% and 58% respectively. Multivariate analysis including all potential influencial factors of posttransplant residual disease recurrence showed that patients after CD34+-PBSCT had a significant higher risk (two times) to develop a MR that patients after BMT (pϽ0.03), whereas patients after PBSCT had a significant lower risk (8 times) for the occurrence of a MR posttransplant (pϽ0.001).
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Long term side effects of G-CSF administration and Peripheral Blood Stem Cell Collection (PBSC) in healthy donors
Ph. Schenck, K. Hö lig, S. Soucek, C. Rutt, G. Ehninger (Tü bingen, Dresden, D) 771 healthy PBSC donors were evaluated regarding side effects of G-CSF administration and leukapheresis. A baseline laboratory investigation was performed at the time of physical examination (PE). G-CSF was given in 2 different dosages (7.5 microgram/ kg BW for 5 days, or 7.5 microgram/kg BW for 2 days and 12.5 microgram/kg BW for the following 3 days) and in intervals of 12 or 24 hours. Leukapheresis was performed on day 5 and if necessary on day 6 with Cobe Spectra, Version 7.0, MNC-protocol. Follow up investigations (questionnaire, CBC with differential, chemistry panel) were carried out 4 weeks, 6 months and then annually (CBC and questionnaire) after donation. Compared with median values at the time of physical examination we found a slight decline in white blood counts and thrombocyte counts. Median counts at time of PE, 4 weeks, 6 months and 1 year after donation in absolute numbers: Leukocytes: 6.33 G/l, 5.12 G/l, 5, 60 G/l, 5, 50 G/l. Neutrophils: 3.94 G/l, 3.05 G/l, 3.3 G/l, 3, 04 G/l. Lymphocytes: 1.73 G/l, 1.38 G/l, 1.60 G/l, 1.59 G/l. Thrombocytes: 258.00 Gpt/l, 225.00 Gpt/l, 238, 17 Gpt/l, 242 .00 Gpt/l. These discrete changes were significant for leukocytes, neutrophils and thrombocytes (pϽ0.001) but not for lymphocytes (pϾ0.05), (values after one year post donation tested against PE-values by Wilcoxon test). Physical complaints of the donors: After 4 weeks 88% stated they were in good health. The remaining 12 % reported: circulatory disorders 1.2 %, gastrointestinal complaints 1.2 %, pain at the puncture site 1.0 %, fatigue 0.6 %, bone pain 0.4 %, headache 0.6 %, flue 1.0 %, bleeding 0.8%, nervousness 0.6 %, toothache 0.6 %, hair loss 0.6 %. Other complaints: 3.0 %. After 6 months 94 % stated, they were in good health without any complaints. 2.3 % felt tired, pain in the joints and limbs 1 %. Other complaints 3.2 % (one donor each): weight loss, eczema, depression, short unconsciousness, sleeplessness, gastrointestinal complaints, hair loss, back ache, infected tooth. One year after donation 91 % of the donors had no physical complaints. The remaining 9 % stated complaints similar to those indicated above. 81,1 % of the donors would donate PBSC a second time, 2,1 % would not and 16,8 % did not answer this question. Conclusions: Lab values were in the normal range after 4 weeks, discrete changes were significant after one year. In long term observation of lab values the influence of attendant circumstances (i.e. stress at the time of PE) and factors before lab analysis are possible explanations for these changes. They will be further investigated which will include various control groups. Between April 1995 and December 1999, 127 patients with HR leukemia (ALL n=77; AML n=24 and CML n=26), lacking an HLA identical family donor, were considered eligible for an Hematopoietic Stem Cell transplant from an unrelated donor. Therefore, the search was simultaneously addressed to the Bone Marrow Donor Worldwide (BMDWW) through the Italian Bone Marrow Donor Registry (IBMDR) and to the CB banks of New York and Netcord Database organization. Search acting was initially successful for 121 patients (95%) and failed to identify either MUD or CB unit only for 6 patients. At a median time of 2 days (1-368) a median of 5 (1-40) suitable CB units was reported by banks for 107 (88%) candidates. The CBT eligibility was fully defined for 56 potential recipients after a median time of 48 days (1-363). According to our selection criteria, 23 patients underwent a CBT at a median time of 106 days (49-321). On the other hand, the preliminary search for MUD recruited a total number of 48840 (median 63, range 1-6772) potential donors for 114 (94%) patients. Because of the administrative procedures, the formal search could be started after a median time of 36 days (1-479) for 88 of 114 patients. Only 34 patients were still eligible for transplant when a definitive donor could be found after a median time of 97 days (34-558) and up to now, 16 patients have been grafted at a median time of 229.5 days (120-614). By comparing CB vs MUD search the analysis of time to full eligibility showed a highly significant difference (48 vs 97 days; p=0.000). Consequently, patients underwent a CBT significantly earlier than recipients of a MUD (106 vs 229.5 days; p=0.000). In our HR patients, relapse was the mean reason of search termination in 41 (32%) patients and of transplant delay in 12 (31%) of 39 transplanted patients. From this prospective study we can draw the conclusion that for leukemia patients at high risk of disease progression the search for an unrelated hematopoietic stem-cell donor should always be addressed to both International Bone Morrow registry and Cord Blood Bank. ; 2-Ag, n=4) and HLA-identical (n=5) volunteer donors for high-risk AL (n=13) and CML (n=3) (group 1). ATG Thymoglobulin" was added to standard dose conditioning at total dosages of 3.5 mg/kg for HLA-identical and 5 mg/kg BW for mismatched SCT. Survival data were compared to 22 historical control pts. receiving SC grafts from HLA-identical (n=18) or 1-Ag mismatched (n=4) volunteer donors for high-risk hematological malignancies between 1992 and 1998 (group 2) after standard-dose conditioning without ATG in 10 pts., in combination with ATG Fresenius (40 mg/kg) in 7 pts., or after dose-intensified 200 mg/kg CY/fTBI combined with 7-10 mg/kg ATG Thymoglobulin" in 5 pts. Post-transplant IS consisted of CsA+MTX according to the standard Seattle protocol in group 2 and of CsA+'mini' MTX (10/m2 on days +1,+3, +6) in group 1. Results: The 2-year probability of OS was 60% for group 1 and 14% for group 2 due to a lower TRM (27% vs 82%). Severe aGVHD III-IV was significantly reduced in group 1 (19 % vs 39%). 5/7 pts. in group 2 and 2/12 in group 1 surviving Ͼ100 days post-transplant developed extensive cGVHD. The RI at two years was 21% in group 2 and 38% in group 1. The incidences of CMV infection/disease were identical for both groups (49% in group 1 vs 50% in group 2). In group 1 high rabbit IgG levels Ͼ12.5 ng/mL were detectable for up to 3-5 weeks and in some patients rabbit IgG levels were even measureable for up to 3m post-transplant. ATG Thymoglobulin" resulted in a significant increase of both serum IL-10 and TNF-a with peak levels on day -1 but without any significant correlation with either transplant-related complications or aGVHD. Conclusions: Addition of risk-adjusted low-dose ATG Thymoglobulin" to standard dose conditioning improves survival after HLA-mismatched unrelated SCT by reducing the risk of severe aGVHD III-IV, TRM and of extensive chronic GVHD in patients surviving Ͼ100 days post-transplant.
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